Next-generation in vivo optical imaging with short-wave infrared quantum dots

Bruns, Oliver T.; Bischof, Thomas; Harris, Daniel K.; Franke, Daniel; Shi, Yanxiang; Riedemann, Lars; Bartelt, Alexander; Jaworski, Frank B.; Carr, Jonathan; Rowlands, Christopher J.; Wilson, Mark W.; Chen, Ou; He, Wei; Hwang, Gyu Weon; Montana, Daniel M.; Coropceanu, Igor; Achorn, Odin B.; Kloepper, Jonas; Heeren, Joerg; So, Peter T. C.; Fukumura, Dai; Jensen, Klavs F.; Jain, Rakesh K.; Bawendi, Moungi G.

doi:10.1038/s41551-017-0056

Cited by 527 publications

(377 citation statements)

References 48 publications

Supporting

Mentioning

377

Contrasting

Order By: Relevance

“…[1] However,t hey still suffer from some inevitable drawbacks such as limited spatial resolution and inability to visualize real-time dynamics. [4] Thus far, inorganic NIR-II contrast agents,i ncluding quantum dots (QDs), [5] single-walled carbon nanotubes (SWNTs), [6] and rare-earth doped downconversion nanoparticles (DCNPs), [1b, 7] have been established for in vivo imaging. [3] Recently,n oninvasive fluorescence imaging in the second near-infrared window (NIR-II, 1000-1700 nm) has attracted immense attention owing to deeper penetration (ca.…”

mentioning

confidence: 99%

An Efficient 1064 nm NIR‐II Excitation Fluorescent Molecular Dye for Deep‐Tissue High‐Resolution Dynamic Bioimaging

et al. 2018

View full text Add to dashboard Cite

A small-molecule fluorophore FD-1080 with both excitation and emission in the NIR-II region has been successfully synthesized for in vivo imaging. A heptamethine structure is designed to shift the absorption and emission into NIR-II region. Sulphonic and cyclohexene groups are introduced to enhance its water solubility and stability. The quantum yield of FD-1080 is 0.31 %, and can be increased to 5.94 % after combining with fetal bovine serum (FBS). Significantly, 1064 nm NIR-II excitation was demonstrated with the high tissue penetration depth and superior imaging resolution compared to previously reported NIR excitation from 650 nm to 980 nm. FD-1080 is not only capable of realizing non-invasive high-resolution deep-tissue hindlimb vasculature and brain vessel bioimaging, but also quantifying the respiratory rate based on the dynamic imaging of respiratory craniocaudal motion of the liver for the awake and anaesthetized mouse.

show abstract

mentioning

confidence: 99%

An Efficient 1064 nm NIR‐II Excitation Fluorescent Molecular Dye for Deep‐Tissue High‐Resolution Dynamic Bioimaging

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Recent research has shown that extending fluorescence imaging into shortwave IR (SWIR; 1,000-2,000 nm) wavelengths can further enhance the advantages of NIR imaging (12)(13)(14)(15). Low levels of background tissue autofluorescence in the SWIR increase imaging sensitivity to a target fluorophore, and the unique tissue absorption and scattering properties increase contrast of structures at greater penetration depths compared with fluorescence imaging in the NIR (13,(16)(17)(18)(19)(20)(21).…”

mentioning

confidence: 99%

Shortwave infrared fluorescence imaging with the clinically approved near-infrared dye indocyanine green

Carr

Franke

Caram

et al. 2018

Proc. Natl. Acad. Sci. U.S.A.

Self Cite

539

552

View full text Add to dashboard Cite

Fluorescence imaging is a method of real-time molecular tracking in vivo that has enabled many clinical technologies. Imaging in the shortwave IR (SWIR; 1,000–2,000 nm) promises higher contrast, sensitivity, and penetration depths compared with conventional visible and near-IR (NIR) fluorescence imaging. However, adoption of SWIR imaging in clinical settings has been limited, partially due to the absence of US Food and Drug Administration (FDA)-approved fluorophores with peak emission in the SWIR. Here, we show that commercially available NIR dyes, including the FDA-approved contrast agent indocyanine green (ICG), exhibit optical properties suitable for in vivo SWIR fluorescence imaging. Even though their emission spectra peak in the NIR, these dyes outperform commercial SWIR fluorophores and can be imaged in the SWIR, even beyond 1,500 nm. We show real-time fluorescence imaging using ICG at clinically relevant doses, including intravital microscopy, noninvasive imaging in blood and lymph vessels, and imaging of hepatobiliary clearance, and show increased contrast compared with NIR fluorescence imaging. Furthermore, we show tumor-targeted SWIR imaging with IRDye 800CW-labeled trastuzumab, an NIR dye being tested in multiple clinical trials. Our findings suggest that high-contrast SWIR fluorescence imaging can be implemented alongside existing imaging modalities by switching the detection of conventional NIR fluorescence systems from silicon-based NIR cameras to emerging indium gallium arsenide-based SWIR cameras. Using ICG in particular opens the possibility of translating SWIR fluorescence imaging to human clinical applications. Indeed, our findings suggest that emerging SWIR-fluorescent in vivo contrast agents should be benchmarked against the SWIR emission of ICG in blood.

show abstract

“…Single-cell imaging techniques that reach beyond current depth limits (that is, ~500 µm), with increased multiplexing (that is, >10 targets imaged simultaneously) are needed to study cancer at the molecular level. A novel class of quantum dots that emit in the short-wave infrared region (SWIR; 1000–2000 nm), where large organisms are rendered translucent for fluorescence imaging 168 , may also become invaluable in the fundamental understanding and treatment of cancer. Improved features of this imaging technique include a lack of autofluorescence, low light absorption by blood and tissue, and reduced scattering.…”

Section: Cellular and Molecular Imagingmentioning

confidence: 99%

Engineering and physical sciences in oncology: challenges and opportunities

2017

Self Cite

View full text Add to dashboard Cite

The principles of engineering and physics have been applied to oncology for nearly 50 years. Engineers and physical scientists have made contributions to all aspects of cancer biology, from quantitative understanding of tumour growth and progression to improved detection and treatment of cancer. Many early efforts focused on experimental and computational modelling of drug distribution, cell cycle kinetics and tumour growth dynamics. In the past decade, we have witnessed exponential growth at the interface of engineering, physics and oncology that has been fuelled by advances in fields including materials science, microfabrication, nanomedicine, microfluidics, imaging, and catalysed by new programmes at the National Institutes of Health (NIH), including the National Institute of Biomedical Imaging and Bioengineering (NIBIB), Physical Sciences in Oncology, and the National Cancer Institute (NCI) Alliance for Nanotechnology. Here, we review the advances made at the interface of engineering and physical sciences and oncology in four important areas: the physical microenvironment of the tumour and technological advances in drug delivery; cellular and molecular imaging; and microfluidics and microfabrication. We discussthe research advances, opportunities and challenges for integrating engineering and physical sciences with oncology to develop new methods to study, detect and treat cancer, and we also describe the future outlook for these emerging areas.

show abstract

Next-generation in vivo optical imaging with short-wave infrared quantum dots

Cited by 527 publications

References 48 publications

An Efficient 1064 nm NIR‐II Excitation Fluorescent Molecular Dye for Deep‐Tissue High‐Resolution Dynamic Bioimaging

An Efficient 1064 nm NIR‐II Excitation Fluorescent Molecular Dye for Deep‐Tissue High‐Resolution Dynamic Bioimaging

Shortwave infrared fluorescence imaging with the clinically approved near-infrared dye indocyanine green

Engineering and physical sciences in oncology: challenges and opportunities

Contact Info

Product

Resources

About